Table 2.
Probe sets with decrease in mean expression after ipilimumab treatment
| Melanoma-associated genes | Cell proliferation-related genes | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Post- versus pre-treatment | Post- versus pre-treatment | ||||||||
| Probe set | Gene | P value | No-CA mean fold change | CA mean fold change | Probe set | Gene | P value | No-CA mean fold change | CA mean fold change |
| 206498_at | OCA2 | 4.3E−03 | −1.2 | −11.1 | 202036_s_at | SFRP1 | 5.9E−04 | −1.5 | −5.6 |
| 206426_at | MLANA | 2.7E−05 | −1.5 | −2.4 | 202037_s_at | SFRP1 | 1.0E−03 | −1.5 | −4.7 |
| 219121_s_at | ESRP1 | 2.7E−03 | −1.3 | −2.1 | 202035_s_at | SFRP1 | 3.9E−03 | −1.2 | −3.9 |
| 209498_at | CEACAM1 | 4.6E−03 | 1.0 | −2.0 | 211804_s_at | CDK2 | 3.4E−03 | −1.5 | −2.5 |
| 218402_s_at | HPS4 | 2.8E−03 | −1.1 | −2.0 | 204252_at | CDK2 | 3.3E−03 | −1.3 | −2.4 |
| 209848_s_at | SILV | 2.0E−03 | −1.4 | −2.0 | 221215_s_at | RIPK4 | 7.1E−03 | −1.1 | −2.0 |
| 206427_s_at | MLANA | 3.3E−05 | −1.4 | −2.0 | 203304_at | BAMBI | 8.6E−04 | −1.2 | −2.0 |
| 219412_at | RAB38 | 1.7E−03 | −1.3 | −2.0 | 201538_s_at | DUSP3 | 6.6E−04 | −1.2 | −2.0 |
| 211889_x_at | CEACAM1 | 1.4E−03 | −1.0 | −1.9 | 213423_x_at | TUSC3 | 4.5E−03 | −1.1 | −2.0 |
| 211883_x_at | CEACAM1 | 2.0E−03 | 1.0 | −1.9 | 208711_s_at | CCND1 | 6.0E−03 | −1.3 | −1.9 |
| 206576_s_at | CEACAM1 | 8.4E−04 | −1.1 | −1.9 | 203628_at | IGF1R | 4.5E−03 | −1.1 | −1.9 |
| 54037_at | HPS4 | 8.0E−03 | −1.1 | −1.9 | 209228_x_at | TUSC3 | 1.3E−03 | −1.2 | −1.9 |
| 218931_at | RAB17 | 5.3E−03 | −1.2 | −1.8 | 203723_at | ITPKB | 4.7E−03 | −1.3 | −1.9 |
| 205694_at | TYRP1 | 1.9E−03 | −1.2 | −1.8 | 202431_s_at | MYC | 3.2E−03 | −1.1 | −1.8 |
| 218211_s_at | MLPH | 1.2E−03 | −1.2 | −1.7 | 203627_at | IGF1R | 9.1E−03 | −1.2 | −1.8 |
| 213139_at | SNAI2 | 6.8E−03 | −1.2 | −1.7 | 220451_s_at | BIRC7 | 1.4E−03 | −1.1 | −1.8 |
| 210467_x_at | MAGEA12 | 5.5E−03 | −1.2 | −1.7 | 206864_s_at | HRK | 1.4E−03 | −1.1 | −1.8 |
| 214603_at | MAGEA2/A2B | 1.1E−03 | −1.2 | −1.7 | 201537_s_at | DUSP3 | 1.4E−03 | −1.2 | −1.8 |
| 209842_at | SOX10 | 3.4E−03 | −1.1 | −1.6 | 213005_s_at | KANK1 | 2.1E−03 | −1.2 | −1.7 |
| 206630_at | TYR | 2.0E−04 | −1.4 | −1.6 | 212607_at | AKT3 | 1.8E−05 | −1.2 | −1.7 |
| 214642_x_at | MAGEA5 | 5.3E−03 | −1.0 | −1.6 | 206865_at | HRK | 1.1E−03 | −1.0 | −1.7 |
| 207233_s_at | MITF | 5.7E−03 | −1.4 | −1.6 | 209108_at | TSPAN6 | 9.3E−03 | −1.2 | −1.7 |
| 214612_x_at | MAGEA6 | 4.7E−03 | −1.2 | −1.5 | 202364_at | MXI1 | 2.1E−03 | −1.1 | −1.7 |
| 209942_x_at | MAGEA3 | 5.8E−03 | −1.2 | −1.5 | 209109_s_at | TSPAN6 | 2.3E−03 | −1.2 | −1.6 |
| 217339_x_at | CTAG1A/1B | 5.8E−03 | −1.1 | −1.5 | 202609_at | EPS8 | 2.8E−04 | −1.2 | −1.6 |
| 209295_at | TNFRSF10B | 2.7E−03 | −1.1 | −1.5 | |||||
| 221577_x_at | GDF15 | 1.7E−03 | −1.2 | −1.5 | |||||
Selected probe sets for melanoma-associated genes (left panel) or cell proliferation-related genes (right panel) with ≥1.5-fold decreases in expression after ipilimumab treatment in the CA group are listed. Fold change in the No-CA group as well as P value for the test of a difference between pre- and post-treatment expression is shown. Mean fold change: positive values give mean of (post-treatment expression)/(pre-treatment expression); negative values give negative mean of (pre-treatment expression)/(post-treatment expression)